Cargando…
Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis
Autores principales: | Kow, Chia Siang, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211145/ https://www.ncbi.nlm.nih.gov/pubmed/32388676 http://dx.doi.org/10.1007/s15010-020-01441-4 |
Ejemplares similares
-
Role of frailty in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis
por: Wei, Xin, et al.
Publicado: (2020) -
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
por: Kow, Chia Siang, et al.
Publicado: (2020)